Adolescent type 1 diabetes mellitus in India

Mohd Ovais* and Mohd Kamil

Faculty of Humanities, Department of Sociology, Shri Venkateshwara University, Gajraula 244 236, India

Diabetes is becoming more common in children and adolescents around the world, with serious consequences for the long-term health of individuals, societies and nations. Diagnosis and management of diabetes in children present several unique challenges. Although type 1 diabetes mellitus (T1DM) is more common in children and adolescents, type 2 diabetes mellitus is also on the rise in young people, particularly among certain ethnic groups. A thorough patient history evolution and physical examination usually reveal the diagnosis. Specific laboratory and imaging tests, however, are required to confirm the diagnosis. Diabetes management in children and adolescents can be difficult in some cases due to age-specific issues and the more aggressive nature of the disease. This study summarizes various sources on how a patient-centred approach focusing on comprehensive risk factor reduction with the involvement of all concerned stakeholders (patients, parents, peers and teachers) could help ensure the best possible level of diabetes control and prevent or delay long-term complications.

Keywords: Children and adolescents, diagnosis and management, hypoglycaemia, insulin, type 1 diabetes mellitus.

TYPE 1 diabetes mellitus (T1DM) is the second most common chronic illness in children, after asthma. Its severity and early mortality are a significant source of suffering[1] and clinical expenses, with diabetes affecting approximately 9% of the US population and costing US$ 174 billion per year[2]. Successful treatments are accessible but require adjusting insulin dosing, diet and exercise alongside continuous input from blood glucose observing outcomes. Such a difficult treatment plan is troublesome for children and adolescents. In any case, increased adherence to diabetes management improves glycemic control[3], resulting in lower haemoglobin A1c (HbA1c) levels, which reduce the risk of diabetes complications[1]. Regardless of the complexity of treatment and repeated interruptions to the life of children and adolescents, treatment becomes more complicated with the interference of painful needles required for blood glucose testing and the disruption of transporting or wearing insulin management devices. Regardless of advances in innovation that make insulin administration easier with pens or pumps, adherence to diabetes regimens is frequently difficult for patients in general but particularly difficult for adolescents[4]. A number of factors combine to make it difficult for youngsters to achieve and maintain their target glycemic control (Figure 1). These include increased concern about society, an early shift in responsibility from guardians to adolescents, a proclivity towards risk-taking, insufficient information about therapy regimens and future health chances, exhaustion from caring for a chronic illness (diabetes burnout) and physiological changes that lead to more significant insulin obstruction during pubescence[5]. Similarly, adherence is likely to become more difficult as providers intensify treatments to improve glycemic control, with the unintended consequence of increasing burden and diminishing well-being advancing practices[6,7]. In this study, we will first consider the barriers to adherence among young adults and then discuss efforts to resolve these issues through promising fieldwork. The underlying themes of effective mediations include responsibility, increasing the number of adolescents upholds (proficient and family), and ongoing psychoeducational tools to promote conduct changes in daily life that favour adherence and lessen the problems that teens face on a daily basis. They often consist of initiatives for patients and their families as well as technological developments that aim to prompt and motivate patients to complete their treatment plans.

*For correspondence. (e-mail: ovaismohd143@gmail.com)

Epidemiology

In a study of 603 children from different scholastic habitats in India, T1DM (89%) was the most persistent etiology[8]. Etiologies like type 2 diabetes mellitus (T2DM) (6%) and fibrocalcific pancreatic diabetes (2%) were inconsistent. The prevalence of T1DM in the subcontinent has not been adequately studied because population-based records have not been established. There is a significant gap in current research in India involving the problem and original records of diabetes among youth. Currently, there are no national databases for patients with juvenile-onset diabetes[9]. With an estimated 77,900 children affected, T1DM is highly prevalent in the South East Asia Region (SEAR). In 2013, T1DM was predicted to affect 12,600 children under 15 years in SEAR[10]. Its prevalence among South Asians and other ethnic groups has been studied in the United Kingdom. In a study conducted in Leicestershire, UK, from 1989 to 1998, the prevalence of T1DM in South Asians was comparable to that of white/different identities (rate per 100,000/yr: 19.2 versus 17.7 in females; 20.3 versus 17.7 in men)[11]. The rate of T1DM in children under the age of 15 years in Yorkshire,



Figure 1. Pathogenesis and natural history of type 1 diabetes mellitus (T1DM). The most recent model expands and revises the conventional model by incorporating information gained from an advanced understanding of the roles of genetics, immunology and environment in the natural history of T1DM[15].

UK, between 1978 and 2007 was higher in non-South Asians (21.5/100,000/yr) than in South Asians (14.7/100,000/yr)[12]. While the growth in South Asians was not statistically significant (1.5%, 1.5% to 4.6%), it was substantially greater than 18 years (1990–2007) (3.4%, 95% CI 2.7–4.2). These results do not provide a clear picture of the prevalence of T1DM in the subcontinent nor precise data on current occurrence patterns (which might be on the increase). It is critical to establish population-based registries for type 1 diabetes in India in order to collect reliable data and thus coordinate public approaches to the issue.

Natural history of type 1 diabetes

By the combined use of genetic autoantibody and metabolic indicators of infection during the past several years, the ability to appreciate the typical history of T1DM has improved dramatically[13]. In fact, a now popular term was created in the middle of the 1980s to include all three of these aspects[14]. Individuals who are genetically predisposed to T1DM and have a fixed number of β-cells are exposed to an environmental trigger, which results in the development of β-cell autoimmunity, according to the natural history of the condition. This process results in a steady and predictable loss of insulin secretory function, which is characterized by the production of islet-reactive autoantibodies and foreshadows the generation of activated autoreactive T cells capable of killing the β-cells. However, several elements of the traditional model have recently been updated to reflect advances in knowledge (Figure 1)[15]. Data, for example, suggest that pancreatic β-cells may survive for a long time in some T1DM patients (i.e. never reach zero in patients with established T1DM)[16]. According to recent research, 40–50% of β-cell destruction may occur at the onset of hyperglycaemia[17], which may be related to the age of the subject, among other factors (e.g. body mass index, physical activity, etc.)[18]. A period of glucose intolerance and clinically 'silent' diabetes, on the other hand, is typically followed by the loss of first-phase insulin response[19]. Recently, there has been much discussion about the 'slope' of β-cell loss in the pre-diabetic phase. Some researchers have suggested that symptoms of the disorder may not appear until after a period of relapsing/remitting autoimmunity[20]. Future T1DM prevention studies must be guided by a better understanding of the natural history of pre-diabetes. These data include the continued identification of genes that control disease susceptibility, a better understanding of autoimmunity/mechanisms underlying immune regulation loss, and the identification of environmental agents that influence the disease. Understanding events (such as the rate of C-peptide loss, presence of residual β-cells, and so on) following the onset of symptoms is also critical for those who have already been diagnosed with the disease.

Genetics

T1DM is a complex, multifaceted disease that does not follow a simple inheritance pattern, despite being significantly influenced by genetic factors[21]. Autoimmunity destroys the pancreatic cells in T1DM, a complex disease with a significant hereditary component. The human leukocyte antigen (HLA) class II genes at 6p21 map to the primary T1DM susceptibility locus, which accounts for up to 30–50% of the hereditary risk. Other non-HLA T1DM loci have less impact on disease risk when compared to HLA. These include the interleukin 2 receptor alpha (*IL2RA*, interferon induced with helicase C domain 1 (*IFIH1*) genes, as well as other newly discovered loci from genomewide association studies. The insulin gene 3 (*INS3*) is located on chromosome 11p15; the polymorphic, cytotoxic T-lymphocyte-associated protein 4 (*CTLA4*) gene is located on chromosome 2q33, and the protein tyrosine phosphatase, non-receptor type 22 (lymphoid) (*PTPN22*) gene is located



Figure 2. Odds ratio for known genes/genetic loci linked to T1DM.

Table 1. Diabetes and a variety of other factors[23]

Factors	Variables	Prevalence of diabetes	Crude odds ratio (OR) (95% CI)	Adjusted OR (95% CI)	Significance
Age in group (yrs)	20–30	12 (6.5)	1	–	–
	31–40	16 (9.5)	1.53 (0.7–3.3)	11.509 (0.68–3.3)	0.309
	41–50	15 (28.3)	5.72 (2.5–13.2)	5.635 (2.3–13.6)	0
	>50	26 (59.1)	20.94 (9.1–48.4)	19.0.001	0.001
Education	Illiterate	32 (19.3)	1	1	0
	Primary, middle school	13 (11.4)	0.54 (0.27–1.8)	1.121 (0.5–2.5)	0.784
	Secondary, higher secondary	19 (15.4)	0.77 (0.41–1.4)	1.325 (0.6–2.9)	0.472
	Graduation, post-graduation	5 (10.4)	0.47 (0.18–1.3)	0.872 (0.2–3.1)	0.834
Occupation	Unemployed	27 (13)	1	1	
	Unskilled, semi-skilled and skilled	30 (15.7)	1.25 (0.71–2.1)	0.89 (0.5–1.8)	0.75
	Clerks, semi and professional	12 (15.3)	2.01 (0.94–4.3)	1.32 (0.5–3.7)	0.602
Habits	Use of tobacco	25 (19.5)	0.65 (0.37–1.1)	1.24 (0.5–2.84)	0.604
	Yes	44 (13.6)	1	1	
	No				
Family history of diabetes	Yes	7 (26.9)	2.16 (0.79–5.7)	0.35 (0.1–1.19)	0.094
	No	62 (14.6)	1	1	
BMI	<22.9	13 (6.3)	1	1	
	23–24.9	5 (5.4)	0.96 (0.33–2.7)	0.998 (0.33–2.9)	0.864
	>25	51 (41.8)	11.66 (6–22.64)	12.704 (6.1–26.1)	0
Duration of stay in Gazipur	Less than 10 years	9 (4.3)	1	1	
	More than 10 years	26 (20)	3.3 (1.2–9)	3.376 (1.48–7.6)	0.004

on chromosome 1p13 (Figure 2)[22]. Table 1 shows the demographic profile and a variety of other factors of diabetes[23].

Diagnostic challenges

In SEAR, T1DM is frequently detected after it has progressed to an advanced stage. When T1DM is first diagnosed, 85–90% of the people have one or more serological markers of β-cell immunological destruction, such as islet cell autoantibodies, glutamic acid decarboxylase (GAD), insulinoma associated antigens (IAs), IA 2 or IA 2β (ref. 24). Strong connections between the disease and HLA might either be protective or predisposing late diagnosis causes delayed insulin administration and early onset of diabetes complications. The prevalence of T2DM among teenagers is on the rise, according to a recent finding in the South Asian population[25]. Moreover, T2DM in young people has been seen as an emerging epidemic within minority youth by paediatric endocrinologists in western countries[26].

Therapy

Until now, the only known safe and effective method by which β-cell death occurs is insulin therapy. Utilizing different types of insulin makes it possible to control blood glucose levels satisfactorily. Moreover, compact insulin implantation pumps, which permit the establishment of a basal insulin profile, are gaining popularity. Therapy with CD3 antibodies has been shown to efficiently restore normoglycemia following β-cell resiliency in the NOD mice[27]. Also, the momentary organization of CD3-explicit antibodies shows promising outcomes in clinical trials[28].

Prevalence of diabetes mellitus

Clinical Experience at Sea – the financial situation and predominate social convictions are closely related to the T1DM challenges faced by the executives in the SEA area. These countries, with their limited medical resources, are

not fully prepared to deal with the complex issues that T1DM entails.

Insulin prescription

Primary care physicians (PCPs) treat a large proportion of diabetes patients in SEAR. Their understanding of the disease and current treatment options, including modern insulin regimens, is limited. Endocrinologist consultations are limited to metropolitan areas and tertiary institutions. So, even when PCPs recommend insulin, it is started late or at a suboptimal dose. Benefits versus associated risks, patient discernment about insulin-prepared therapy, and preparation with regard to the numerous insulin regimens available are the main concerns of PCPs when starting an insulin treatment[29].

Monitoring and therapy

Self-care is a crucial component of T1DM management. Medicine consistency, self-monitoring of blood glucose (SMBG), smart dieting and adhering to an ideal exercise plan are fundamental patient practices that hindering ideal blood glucose control[30]. Following these critical practices has proven to be extremely beneficial for T1DM patients. According to the studies, only 30% of people with diabetes follow the recommended drug regimen[31]. Inconvenience caused by regular injections and the perceived inconvenience of insulin organization also play a significant role in non-adherence to insulin treatment. It has been observed that patients generally do less than the required SMBG, resulting in poor glycemic control[32]. The vast majority of young T1DM patients attend regular schools or universities.

Hypoglycaemia

Hypoglycaemia is a common and potentially dangerous side effect of insulin therapy. Juvenile T1DM patients are vulnerable to hypoglycaemia due to unpredictable dietary habits, unique food choices and sporadic exercise plans. Patients receiving delayed insulin treatment have been observed to have reduced hypoglycaemia discernment[33].

T1DM in India

Despite the fact that T2DM accounts for more than 95% of cases in India, a large proportion of patients have T1DM. T1DM frequently develops between the ages of 5 and 7 years, which is a critical period for social and mental development. While the young parents are attempting to establish themselves in their professional careers, the child is attempting to adjust to the demanding routine and schedule of school life. Parents and young patients must make significant lifestyle changes due to the strict T1DM monitoring and treatment regimen[34].

Patient factors

For insulin-based regimens, regular blood sugar checks and insulin delivery using an insulin pump or multiple daily injections (MDI) are required. Less than 0.5% of patients adhere to this treatment strategy. While undergoing rigorous treatment, young patients are expected to compete with their classmates in academic and extracurricular activities. This hectic schedule causes significant variations and virtually no time for blood glucose monitoring. The school administration is also unhelpful because the children must monitor his/her blood glucose and self-inject insulin before lunch. Their repeated requests to use the restroom are sometimes refused. Due to parental pressure, these young patients participate in extracurricular activities such as dance, swimming and other high-energy sports, which add stress to the already precariously balanced underlying homeostasis. Patients are unable to perform even mild activities that would be helpful because a reasonable dietary arrangement that regulates the calorie demand and blood glucose is not followed.

Marriage can be stressful for a person with diabetes and his/her family because it may be difficult to find a compatible spouse. This is particularly true for female patients. There have been reports of a newlywed girl developing diabetic acidosis and its complications as a result of skipping insulin.

Other behavioural problems also prevent T1DM from being successfully managed. Despite receiving free glucometers and test strips, patients do not adhere to SMBG. The prescribed regimen is not followed because of cost-related issues, lack of knowledge and worry about adverse consequences, including weight gain or hypoglycaemia. Due to considerations relating to their employment, diabetic patients often conceal their medical status[35].

Delhi

The commonness of diabetes has arrived at scourge extents in our country especially in metropolitan regions. At present roughly 73 million grown-ups are assessed to have diabetes in India[36]. One of the most punctual multi-centre investigations in India to assess the commonness of diabetes was done by ICMR in metropolitan and rustic spaces of six Indian urban areas and revealed a mean pervasiveness of 2.1% in metropolitan regions and 1.5% in provincial regions. The mean commonness in Delhi was 0.9% in this examination[37]. Since then, diabetes has become more common in the country, as well as in Delhi. Study in 1986 revealed that diabetes prevalence was much higher than previously considered, with a long absolute predominance of 6.4% (ref. 38). Following this, numerous studies have revealed that the prevalence of diabetes has steadily increased over the last 30 years[39–44], surpassing 10% in many studies conducted after 2000 (ref. 45).

NUDS[46] and ICMR-INDIAB[47] are two such studies that surveyed Delhi as well. While the ICMR-INDIAB findings from Delhi have not yet been released, the prevalence of diabetes and prediabetes in NUDS in 2001 was 11.6% and 8.6% respectively. Given that almost one-fifth of Delhi's adult population had diabetes or was at risk for developing the same, the statistics show the significant health burden of diabetes. Two additional studies from Delhi have reported on the prevalence of diabetes[48,49]. The study by Misra *et al.*[48] was limited to slum-dwellers in Delhi, whereas Verma *et al.*[49] focused solely on the prevalence of diabetes in East Delhi. According to the WHO and ADA criteria, it has been estimated that over 40% and around 60% of the study population respectively, had glucose intolerance. Diabetes affected nearly 20% of the population, but the prevalence of prediabetes ranged from 20% to 40%, depending on whether the WHO or ADA criteria were used. These diabetes prevalence figures for Delhi are a matter of concern and indicate that the city bears a significant burden. They could also be a sign of the rising prevalence of diabetes in India's major cities. Obesity rates have been linked to a variety of factors, including lifestyle changes, economic transitions, internal migration to metropolitan areas and stress[50].

Diabetes management barriers and challenges

It is widely accepted that early insulin administration is required for strict glucose control and to delay the onset of various problems[51]. Despite the fact that many Indians with diabetes do not meet their glycemic goals[52], a Diabetes Attitudes, Wishes, and Needs (DAWN) survey found that Indian clinicians delay the introduction of insulin compared to doctors in 12 other countries[53]. Such delay in insulin administration, which is associated with insulin recognition in patients, is related to the physicians' perceptions of insulin[53].

Doctors' and patients' perceptions of the efficacy and safety of insulin are influenced by their understanding of the benefits of insulin therapy. Treatment acceptability recommendations are significantly influenced by the ease of organization and flexibility of utilization. Since insulin treatment interferes with eating, exercising and daily activities, patients complain that it is poorly planned and experience frustration from hypoglycaemia, infusion pain, the time required to manage the disease and embarrassment.

Storage, safety and availability of insulin

A sizable proportion of the Indian populace lives in rural areas where medical services are inadequate. The ability to obtain insulin in these areas is a key test for determining the treatment goals. Additionally, refrigeration is necessary to maintain the specific temperature range required to store insulin. Capacity accordingly requires a steady inventory of power, which cannot be guaranteed in country zones and towns in these nations[54]. Recent findings from the DAWN study revealed that patients receiving insulin treatment revealed concern more frequently about hypoglycaemia (25–55%) and weight gain (40%), both internationally (about half) and in India. The start and increase of insulin have been delayed due to patient and physician anxiety about hypoglycaemia episodes (daylong, night-time and intense) and weight gain[55]. The cardiovascular complications linked to high blood glucose levels may also contribute to delaying the introduction of insulin for strict glycemic control by doctors[56]. Additionally, it was found that disease incidence was linked to the use of insulin and insulin analogs, raising concerns about their potential for mitogenic activity[57]. These concerns cause a delay in the initiation and intensification of the insulin response, resulting in poor glycemic control and the development of auxiliary complications[58].

Behavioural and psychological issues

When T1DM is diagnosed, patients and their relatives must make considerable lifestyle modifications. SMBG and MDI require a high level of control. Such stringent dosing and testing requirements could be extremely difficult to meet. In addition, careful dietary planning and calorie monitoring are required to maintain a delicate balance between the needs of development and preventing hyperglycaemia[59].

Socio-cultural factors and lack of awareness

Improper T1DM administration is also due to ignorance and lack of education. The patients and their guardians cannot follow the proper instructions given by medical care providers or do not fully understand the consequences of the disease. While some people treat diabetes with local remedies that need logical thought and testing, others regard it as a serious disease and a punishment for past transgressions[60].

Economic restriction

T1DM monitoring, treatment or hospitalization incurs high costs. There are no supported or regulated payback methods for its administration in SEAR. The small amount of GDP spent on welfare results in the lack of a Government-supported framework that needs to be strengthened overall in these nations. In order to understand how T1DM affects organs, it is also important to review your lipid profile, circulatory strain, and renal files. The T1DM executives' general costs go up as a result of these boundaries being checked[35].

Etiology and pathogenesis

Generally, congenital association with T1DM is identical among Indians and Caucasians. DRB1*03/DQB1*02 alleles

are most strongly associated with HLA affiliation in North Indians, whereas DRB1*04/DQB1*03 alleles are weak or nonexistent[61]. Antibodies to the islet antigens, GAD, IA2 and insulin are used to diagnose islet autoimmunity. While the prevalence of GAD (42%) was comparable to that of European immigrant children, IA2 recurrence was much lower (33% versus 70%) in a study of recently diagnosed Indian T1DM patients[47]. Both GAD and IA2 antibodies were absent in 45% of patients with later-onset diabetes, indicating that idiopathic (type 1B) patients were significantly more common than reported in other Caucasian populations (10%)[62].

Clinical aspects

T1DM was rarely distinguished from other less persistent forms of insulin-dependent diabetes, such as fibrocalcific pancreatic diabetes and diabetes associated with malnutrition. In a study of 160 T1DM patients of different financial statuses currently being conducted in a multidisciplinary facility in Lucknow, North India, HbA1c (8.0% ±1.5%), recurrence of hypoglycaemia (3.3 incidents/100 patient-years) and ketoacidosis (5.0 incidents/100 patient-years) were comparable to those reported from the developed countries[63]. Furthermore, due to the high costs and general reluctance of families, home blood glucose monitoring (and thus insulin portion adjustment) was infrequently performed. T1DM care in India are negatively impacted by several economic and social concerns. Financial concerns are crucial, especially for low-income and middle-class families that lack access to universal protection and free or subsidized healthcare. According to estimates, the immediate expenses on a centre and a low-income household for treating T1DM range from 32% to 59% of the total family income[35].

Convenience and lifestyle

Insulin regimen rigidity in terms of organization and other aspects may contribute to the patients' perceptions of insulin therapy interfering with their daily lives. Injecting at a specific time of day, particularly in public places, may cause inconvenience and humiliation, which, when combined with a busy lifestyle, leads to poor compliance[64]. Similarly, several patients described self-checking their blood sugar levels as uncomfortable and agonizing and did not sufficiently consent to the monitoring[65].

Children with T1DM who receive evening infusions at school and frequently forget dosages are furnished. Similarly, a few patients additionally detailed self-checking their blood glucose levels as awkward and excruciating and do not adequately consent to the monitoring[66]. A DAWN study showed medication resistance between 85% and 90% of Indian patients, supporting the results of another study that also found low levels of adherence to treatment[67].

New generation onset diabetes – management concern

The majority of T1DM patients would require multiple daily insulin injections or a continuous subcutaneous insulin mixture pump to control their diabetes. Insulin and metformin are the only medications approved for the treatment of T2DM in children and adolescents[68]. Furthermore, these children are likely to have other cardiovascular risk factors, such as hypertension and abnormal lipid profiles, which necessitate treatment in accordance with age-specific guidelines.

Continuous glucose monitoring

It is critical to conduct regular glucose self-monitoring (e.g. four or more times a day). This is accomplished by using continuous glucose monitoring devices, which measure the glucose level in your body's interstitial fluid and translate it into a reading of your blood glucose. HbA1c should be measured every two to six months in order to monitor blood glucose control and must be mentioned between 6.5% and 7.5%. Pumps are among the newest technologies for managing insulin and monitoring blood glucose. Pump therapy can lower the risk of hypoglycaemia while increasing lifestyle flexibility. Real-time continuous glucose monitoring devices provide detailed information on glucose patterns and trends, as well as alarms in response to hyper- and hypoglycaemia[69].

Exercise

A healthy weight can be attained or maintained by exercise, which also improves the ability of insulin to reduce blood glucose levels. On most days of the week, one should strive for 30–60 min of exercise. One must carry glucose tablets or carbohydrate-rich food or beverage, like fruit or juice when working out in case the blood glucose levels drop too low[70]. Exercise should be avoided if blood glucose levels are higher than 250 mg/dl because insulin is insufficient, and blood glucose levels rise immediately after exercise because muscles convert glycogen to glucose. It is therefore recommended to check blood glucose levels before and after exercise[71].

Sick day management

Being unwell is stressful on the body, and the stress hormones released during illness stimulate the liver to create extra glucose, which causes hyperglycaemia. As a result, it is important to regularly monitor blood glucose levels and modify insulin dosage as necessary[72].

Reasons for high fasting sugars

High fasting blood sugar can occasionally occur even when exercising and eating properly. The explanations include:

(a) When waking up, the body prepares to consume more food, and the liver delivers more glucose into the circulatory system. In diabetics there is no insulin to coordinate with the early morning rise; thus morning blood sugars are high. This occurs between 3 and 8 a.m. and can be treated by increasing basal insulin measurements[73]. (b) Somogyi effect (bounce-back hyperglycaemia) – when too much or too little insulin is taken before bed, glucose levels drop sharply for a short period. The body responds by producing chemicals that neutralize insulin, resulting in hyperglycaemia. A hypoglycaemia will be encountered in the middle of the night[73]. (c) To know whether one is encountering Dawns, or Somogyi wonder, one should check glucose at 3 am. If blood glucose is low (less than 70 mg/dl), it is the Somogyi effect; if it is high (greater than 210 mg/dl), it is the Dawn effect[73]. (d) During the luteal stage in women (the time between ovulation and the start of the period), insulin resistance is high due to higher oestrogen and progesterone levels (during the week preceding the first day of the period), and thus fasting glucose levels increase[74].

Travelling

Diabetic supplies must be carried in a separate bag, including extra insulin, a glucometer and injection needles. One must also carry enough food to avoid hypothermia. In the case of voyaging west, the 24-hour day is expanded so cover these additional hours by taking fast acting insulin (bolus insulin) with food. Then, at that point take foundation insulin at the typical time in the appearance time region. In the case of voyaging east, the day is abbreviated. Take fast acting insulin with dinners and a diminished portion of foundation insulin at the ordinary time in the flight time region. Then, at that point take an ordinary portion at typical time in the appearance time region[75].

Conclusion

Diabetes is the most widely recognized endocrine disorder in children and adolescents worldwide. It poses a few interesting challenges: the differential determination is broad, and the clinical course is likely more forceful. In addition to the prolonged hyperglycaemia, diabetes has intrinsic force and is difficult to manage in children, making problems more likely to occur. Unfortunately, the diagnosis of diabetes is frequently delayed (except in T1DM), resulting in prolonged periods of uncontrolled hyperglycaemia and the subsequent risk of severe and ongoing complications. Despite having diabetes, these young people will live long and free of complications if they receive an early and accurate diagnosis, regular follow-ups, and maintain excellent glycemic and risk factor control through prudent use of the currently available treatment options.

Funding sources: This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Conflict of interest: The authors declare that there is no conflict of interest.

1. Nathan, D. M. *et al*., Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl. J. Med*., 1993, **329**(14), 977–986; doi:10.1056/NEJM199309303291401.
2. American Diabetes Association, Economic costs of diabetes in the US in 2012. *Diabetes Care*, 2013, **36**(4), 1033–1046.
3. Hood, K. K., Rohan, J. M., Peterson, C. M. and Drotar, D., Interventions with adherence-promoting components in pediatric type 1 diabetes: meta-analysis of their impact on glycemic control. *Diabetes Care*, 2010, **33**(7), 1658–1664; doi:10.2337/dc09-2268.
4. Morris, A. D., Boyle, D. I., McMahon, A. D., Greene, S. A., MacDonald, T. M. and Newton, R. W., Adherence to insulin treatment, glycaemic control, and ketoacidosis in insulin-dependent diabetes mellitus. The DARTS/MEMO collaboration, Diabetes audit and research in Tayside Scotland. Medicines monitoring unit. *Lancet*, 1997, **350**(9090), 1505–1510; doi:10.1016/s0140-6736(97)06234-x.
5. Amiel, S. A., Sherwin, R. S., Simonson, D. C., Lauritano, A. A. and Tamborlane, W. V., Impaired insulin action in puberty. A contributing factor to poor glycemic control in adolescents with diabetes. *N. Engl. J. Med*., 1986, **315**(4), 215–219; doi:10.1056/NEJM198607243150402.
6. Ingersoll, G. M., Orr, D. P., Herrold, A. J. and Golden, M. P., Cognitive maturity and self-management among adolescents with insulin-dependent diabetes mellitus. *J. Pediatric*., 1986, **108**(4), 620–623; doi:https://doi.org/10.1016/S0022-3476(86)80852-6.
7. Silverstein, J. *et al*., Care of children and adolescents with type 1 diabetes: a statement of the American Diabetes Association. *Diabetes Care*, 2005, **28**(1), 186–212; doi:10.2337/diacare.28.1.186.
8. Unnikrishnan, A. G. *et al*., Type 1 diabetes versus type 2 diabetes with onset in persons younger than 20 years of age. *Ann. N.Y. Acad. Sci*., 2008, **1150**, 239–244; doi:10.1196/annals.1447.056.
9. Praveen, P. A. *et al*., Registry of youth onset diabetes in India (YDR) rationale, recruitment, and current status. *J. Diabetes Sci. Technol*., 2016, **10**(5), 1034–1041; doi:10.1177/1932296816645121.
10. Amutha, A. and Mohan, V., Childhood and adolescent onset type 1 diabetes in India. *MGM J. Med. Sci*., 2013; doi:10.5005/jp-journals-10036-1013.
11. Raymond, N. T. *et al*., Comparative incidence of type I diabetes in children aged under 15 years from South Asian and white or other ethnic backgrounds in Leicestershire, UK, 1989 to 1998. *Diabetologia* (*Suppl.*), 2001, **44**(3), B32–B36; doi:10.1007/pl00002951.
12. Harron, K. L. *et al*., Incidence rate trends in childhood type 1 diabetes in Yorkshire, UK 1978–2007: effects of deprivation and age at diagnosis in the South Asian and non-South Asian populations. *Diabet. Med*., 2011, **28**(12), 1508–1513; doi:10.1111/j.1464-5491.2011.03413.x.
13. Atkinson, M. A., ADA Outstanding Scientific Achievement Lecture 2004. Thirty years of investigating the autoimmune basis for type 1 diabetes: why can't we prevent or reverse this disease? *Diabetes*, 2005, **54**(5), 1253–1263; doi:10.2337/diabetes.54.5.1253.
14. Eisenbarth, G. S., Type I diabetes mellitus. A chronic autoimmune disease. *N. Engl. J. Med*., 1986, **314**(21), 1360–1368; doi:10.1056/NEJM198605223142106.
15. Atkinson, M. A. and Eisenbarth, G. S., Type 1 diabetes: new perspectives on disease pathogenesis and treatment (published correction appears in *Lancet*, 2001, **358**(9283), 766). *Lancet*, 2001, **358**(9277), 221–229; doi:10.1016/S0140-6736(01)05415-0.

16. Meier, J. J., Bhushan, A., Butler, A. E., Rizza, R. A. and Butler, P. C., Sustained beta cell apoptosis in patients with long-standing type 1 diabetes: indirect evidence for islet regeneration? *Diabetologia*, 2005, **48**(11), 2221–2228; doi:10.1007/s00125-005-1949-2.
17. Akirav, E., Kushner, J. A. and Herold, K. C., Beta-cell mass and type 1 diabetes: going, going, gone? *Diabetes*, 2008, **57**(11), 2883–2888; doi:10.2337/db07-1817.
18. Matveyenko, A. V. and Butler, P. C., Relationship between beta-cell mass and diabetes onset. *Diabetes Obes. Metab*. (*Suppl. 4*), 2008, **10**, 23–31; doi:10.1111/j.1463-1326.2008.00939.x.
19. Sosenko, J. M. *et al*., Glucose excursions between states of glycemia with progression to type 1 diabetes in the diabetes prevention trial-type 1 (DPT-1). *Diabetes*, 2010, **59**(10), 2386–2389; doi:10.2337/db10-0534.
20. von Herrath, M., Sanda, S. and Herold, K., Type 1 diabetes as a relapsing–remitting disease? *Nature Rev. Immunol*., 2007, **7**(12), 988–994; doi:10.1038/nri2192.
21. Noble, J. A. and Erlich, H. A., Genetics of type 1 diabetes. *Cold Spring Harb. Perspect. Med*., 2012, **2**(1), a007732; doi:10.1101/cshperspect.a007732.
22. Steck, A. K. and Rewers, M. J., Genetics of type 1 diabetes. *Clin. Chem*., 2011, **57**(2), 176–185; doi:10.1373/clinchem.2010.148221.
23. Bala, S., Pandve, H., Kamala, K., Dhanalakshmi, A. and Sarikonda, H., Performance of Indian diabetic risk score as a screening tool of diabetes among women of industrial urban area. *J. Fam. Med. Prim. Care*, 2019, **8**(11), 3569–3573; doi:10.4103/jfmpc.jfmpc_799_19.
24. American Diabetes Association, Diagnosis and classification of diabetes mellitus. *Diabetes Care* (*Suppl. 1*), 2012, **35**, S64–S71.
25. Bajaj, S. *et al*., South Asian women with diabetes: psychosocial challenges and management: consensus statement. *Indian J. Endocrinol. Metab*., 2013, **17**(4), 548–562; doi:10.4103/2230-8210.113720.
26. Rosenbloom, A. L., Joe, J. R., Young, R. S. and Winter, W. E., Emerging epidemic of type 2 diabetes in youth. *Diabetes Care*, 1999, **22**(2), 345–354; doi:10.2337/diacare.22.2.345.
27. Chatenoud, L., Thervet, E., Primo, J. and Bach, J. F., Anti-CD3 antibody induces long-term remission of overt autoimmunity in nonobese diabetic mice. *Proc. Natl. Acad. Sci. USA*, 1994, **91**(1), 123–127; doi:10.1073/pnas.91.1.123.
28. Chatenoud, L., CD3-specific antibody-induced active tolerance: from bench to bedside. *Nature Rev. Immunol*., 2003, **3**(2), 123–132; doi:10.1038/nri1000.
29. Hayes, R. P., Fitzgerald, J. T. and Jacober, S. J., Primary care physician beliefs about insulin initiation in patients with type 2 diabetes. *Int. J. Clin. Pract*., 2008, **62**(6), 860–868; doi:10.1111/j.1742-1241.2008.01742.x.
30. American Association of Diabetes Educators, AADE7 self-care behaviors. *Diabetes Educ*., 2008, **34**, 445–449.
31. Kotwani, A. *et al*., Prices and availability of common medicines at six sites in India using a standard methodology. *Indian J. Med. Res*., 2007, **125**(5), 645–654.
32. Berlin, I. *et al*., Phobic symptoms, particularly the fear of blood and injury, are associated with poor glycemic control in type I diabetic adults. *Diabetes Care*, 1997, **20**(2), 176–178; doi:10.2337/diacare.20.2.176.
33. Pramming, S., Thorsteinsson, B., Bendtson, I. and Binder, C., Symptomatic hypoglycaemia in 411 type 1 diabetic patients. *Diabet. Med*., 1991, **8**(3), 217–222; doi:10.1111/j.1464-5491.1991.tb01575.x.
34. Das, A. K., Type 1 diabetes in India: overall insights. *Indian J. Endocrinol. Metab*. (*Suppl. 1*), 2015, **19**, S31–S33; doi:10.4103/2230-8210.155372.
35. Kesavadev, J. *et al*., Challenges in type 1 diabetes management in South East Asia: descriptive situational assessment. *Indian J. Endocrinol. Metab*., 2014, **18**(5), 600–607; doi:10.4103/2230-8210.139210.
36. East, M. and Africa, N., IDF Diabetes Atlas, 2017, 8th edn, pp. 20, 79.
37. Anjana, R. M. *et al*., The need for obtaining accurate nationwide estimates of diabetes prevalence in India – rationale for a national study on diabetes. *Indian J. Med. Res*., 2011, **133**(4), 369–380.
38. Verma, N. P., Mehta, S. P., Madhu, S., Mather, H. M. and Keen, H., Prevalence of known diabetes in an urban Indian environment: the Darya Ganj diabetes survey. *Br. Med. J. (Clin. Res. Ed.)*, 1986, **293**(6544), 423–424; doi:10.1136/bmj.293.6544.423.
39. Ramachandran, A., Jali, M. V., Mohan, V., Snehalatha, C. and Viswanathan, M., High prevalence of diabetes in an urban population in South India. *BMJ*, 1988, **297**(6648), 587–590; doi:10.1136/bmj.297.6648.587.
40. Ramachandran, A., Snehalatha, C., Dharmaraj, D. and Viswanathan, M., Prevalence of glucose intolerance in Asian Indians. Urban–rural difference and significance of upper body adiposity. *Diabetes Care*, 1992, **15**(10), 1348–1355; doi:10.2337/diacare.15.10.1348.
41. Ramachandran, A., Snehalatha, C., Latha, E., Vijay, V. and Viswanathan, M., Rising prevalence of NIDDM in an urban population in India. *Diabetologia*, 1997, **40**(2), 232–237; doi:10.1007/s0012500-50668.
42. Ramachandran, A., Snehalatha, C., Latha, E., Manoharan, M. and Vijay, V., Impacts of urbanisation on the lifestyle and on the prevalence of diabetes in native Asian Indian population. *Diabetes Res. Clin. Pract*., 1999, **44**(3), 207–213; doi:10.1016/s0168-8227(99)00-024-8.
43. Ramaiya, K. L., Kodali, V. R. and Alberti, K. G., Epidemiology of diabetes in Asians of the Indian subcontinent. *Diabetes Metab. Rev*., 1990, **6**(3), 125–146; doi:10.1002/dmr.5610060302.
44. Mohan, V. *et al*., Intra-urban differences in the prevalence of the metabolic syndrome in southern India – the Chennai Urban Population Study (CUPS No. 4). *Diabet. Med*., 2001, **18**(4), 280–287; doi:10.1046/j.1464-5491.2001.00421.x.
45. Madhu, S. V., Sandeep, G., Mishra, B. K. and Aslam, M., High prevalence of diabetes, prediabetes and obesity among residents of East Delhi – The Delhi Urban Diabetes Survey (DUDS). *Diabetes Metab. Syndr*., 2018, **12**(6), 923–927; doi:10.1016/j.dsx.2018.05.016.
46. Ramachandran, A. *et al*., High prevalence of diabetes and impaired glucose tolerance in India: National Urban Diabetes Survey. *Diabetologia*, 2001, **44**(9), 1094–1101; doi:10.1007/s001250100627.
47. Anjana, R. M. *et al*., Prevalence of diabetes and prediabetes (impaired fasting glucose and/or impaired glucose tolerance) in urban and rural India: phase I results of the Indian Council of Medical Research-INdia DIABetes (ICMR-INDIAB) study. *Diabetologia*, 2011, **54**(12), 3022–3027; doi:10.1007/s00125-011-2291-5.
48. Misra, A., Pandey, R. M., Devi, J. R., Sharma, R., Vikram, N. K. and Khanna, N., High prevalence of diabetes, obesity and dyslipidaemia in urban slum population in northern India (published correction appears in *Int. J. Obes. Relat. Metab. Disord.*, 2002, **26**(9), 1281). *Int. J. Obes. Relat. Metab. Disord*., 2001, **25**(11), 1722–1729; doi:10.1038/sj.ijo.0801748.
49. Verma, N. P. and Madhu, S. V., Prevalence of known diabetes in urban east Delhi. *Diabet. Res. Clinic. Prac*., 2000, **50**, 124; ISSN: 0168-8227.
50. Bhardwaj, S., Misra, A., Khurana, L., Gulati, S., Shah, P. and Vikram, N. K., Childhood obesity in Asian Indians: a burgeoning cause of insulin resistance, diabetes and sub-clinical inflammation. *Asia Pac. J. Clin. Nutr*. (*Suppl. 1*), 2008, **17**, 172–175.
51. Porcellati, F. *et al.*, Glucagon as a therapeutic approach to severe hypoglycemia: after 100 years, is it still the antidote of insulin? *Biomolecules*, 2021, **27**, 11(9), 1281; doi:10.3390/biom11091281.
52. Patton, S. R., Dolan, L. M., Henry, R. and Powers, S. W., Fear of hypoglycemia in parents of young children with type 1 diabetes mellitus. *J. Clin. Psychol. Med. Settings*, 2008, **15**(3), 252–259; doi:10.1007/s10880-008-9123-x.
53. Funnell, M. M., The diabetes attitudes, wishes, and needs (DAWN) study. *Clinic. Diabet*., 2006, **24**(4), 154–155; doi:10.2337/diaclin.24.4.154.
54. Greaves, C. J., Brown, P., Terry, R. T., Eiser, C., Lings, P. and Stead, J. W., Converting to insulin in primary care: an exploration of the needs of practice nurses. *J. Adv. Nurs.*, 2003, **42**(5), 487–496; doi:10.1046/j.1365-2648.2003.02648.x.

55. Korytkowski, M., When oral agents fail: practical barriers to starting insulin. *Int. J. Obes*., 2002, **26**(3), S18–S24; doi:https://doi.org/10.1038/sj.ijo.0802173.
56. Peyrot, M., Barnett, A. H., Meneghini, L. F. and Schumm-Draeger, P. M., Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. *Diabet. Med*., 2012, **29**(5), 682–689; doi:10.1111/j.1464-5491.2012.03605.x.
57. Hemkens, L. G., Grouven, U., Bender, R., Günster, C., Gutschmidt, S., Selke, G. W. and Sawicki, P. T., Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. *Diabetologia*, 2009, **52**(9), 1732–1744.
58. Chudyk, A., Shapiro, S., Russell-Minda, E. and Petrella, R., Self-monitoring technologies for type 2 diabetes and the prevention of cardiovascular complications: perspectives from end users. *J. Diabet. Sci. Technol*., 2011, **5**(2), 394–401; doi:10.1177/19322968110-0500229.
59. Palerm, C. C., Zisser, H., Jovanovič, L. and Doyle III, F. J., A run-to-run control strategy to adjust basal insulin infusion rates in type 1 diabetes. *J. Process Control*, 2008, **18**(3–4), 258–265; doi:10.1016/j.jprocont.2007.07.010.
60. Wangnoo, S. K. *et al.*, Barriers and solutions to diabetes management: an Indian perspective. *Indian J. Endocrinol. Metab*., 2013, **17**(4), 594; doi:10.4103/2230-8210.113749.
61. Kumar, N., Mehra, N. K., Kanga, U., Kaur, G., Tandon, N., Chuzho, N., Mishra, G. and Neolia, S. C., Diverse human leukocyte antigen association of type 1 diabetes in north India. *J. Diabetes*, 2019, **11**(9), 719–728; doi:10.1111/1753-0407.12898.
62. Pozzilli, P. and Pieralice, S., Latent autoimmune diabetes in adults: current status and new horizons. *Endocrinol. Metabol*., 2018, **33**(2), 147–159; doi:10.3803/EnM.2018.33.2.147.
63. Grundy, S. M. *et al.*, Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. *Circulation*, 1999, **100**(10), 1134–1146; doi:10.1161/01.cir.100.10.1134.
64. Church, T. J. and Haines, S. T., Treatment approach to patients with severe insulin resistance. *Clinic. Diabet*., 2016, **34**(2), 97–104; doi:10.2337/diaclin.34.2.97.
65. Hortensius, J., Slingerland, R. J., Kleefstra, N., Logtenberg, S. J., Groenier, K. H., Houweling, S. T. and Bilo, H. J., Self-monitoring of blood glucose: the use of the first or the second drop of blood. *Diabetes Care*, 2011, **34**(3), 556–560; doi:10.2337/dc10-1694.
66. Cummins, E., Royle, P., Snaith, A., Greene, A., Robertson, L., McIntyre, L. and Waugh, N., Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. *Health Technol. Assess.* (*Winchester, England*), 2010, **14**(11), iii–v; doi:10.3310/hta14110.
67. Peyrot, M. *et al.*, International DAWN Advisory Panel. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. *Diabetes Care*, 2005, **28**(11), 2673–2679; doi:10.2337/diacare.28.11.2673.
68. Swinnen, S. G., Hoekstra, J. B. and DeVries, J. H., Insulin therapy for type 2 diabetes. *Diabetes Care*, 2009, **32**(suppl_2), S253–S259; doi:10.2337/dc09-S318.
69. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. *New England J. Med*., 2008, **359**(14), 1464–1476; doi:10.1056/NEJMoa0805017.
70. Parchman, L. M. and Franz, M. J., *Your Guide to Diabetes: Type 1 and Type 2*, NIH Publication, 2013, No. 14-4016.
71. Rubio-Cabezas, O., Hattersley, A. T., Njølstad, P. R., Mlynarski, W., Ellard, S., White, N. and Craig, M. E., The diagnosis and management of monogenic diabetes in children and adolescents. *Pediatric Diabet.*, 2014, **15**(S20), 47–64; doi:10.1111/pedi.12192.
72. Phelan, H. *et al.*, Sick day management in children and adolescents with diabetes. *Pediatric Diabet*., 2022, **23**(7), 912–925; doi:https://doi.org/10.1111/pedi.13415.
73. Rybicka, M., Krysiak, R. and Okopień, B., The dawn phenomenon and the Somogyi effect – two phenomena of morning hyperglycaemia. *Pol. J. Endocrinol*., 2011, **62**(3), 276–283.
74. Gaete, X., Vivanco, M., Eyzaguirre, F. C., López, P., Rhumie, H. K., Unanue, N. and Codner, E., Menstrual cycle irregularities and their relationship with HbA1c and insulin dose in adolescents with type 1 diabetes mellitus. *Fertility Sterility*, 2010, **94**(5), 1822–1826; doi:https://doi.org/10.1016/j.fertnstert.2009.08.039.
75. Ghosh, S. *et al.*, Diabetes and travel. *Int. J. Diabet. Develop. Countr*., 2018, **38**, 4–10; doi:https://doi.org/10.1007/s13410-018-0605-6.

Received 11 August 2022; revised accepted 6 December 2022

doi: 10.18520/cs/v124/i7/790-798